



## **Kiniksa Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference**

January 3, 2022

HAMILTON, Bermuda, Jan. 03, 2022 (GLOBE NEWSWIRE) -- [Kiniksa Pharmaceuticals, Ltd.](https://www.kiniksa.com) (Nasdaq: KNSA) announced today that it will present at the 40<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 1:30 p.m. Eastern Time.

A live webcast of Kiniksa's presentation will be accessible through the Investors & Media section of the company's website at [www.kiniksa.com](https://www.kiniksa.com). A replay of the webcast will also be available on Kiniksa's website within approximately 48 hours after the event.

### **About Kiniksa**

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio assets, ARCALYST<sup>®</sup> (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit [www.kiniksa.com](https://www.kiniksa.com).

ARCALYST<sup>®</sup> is a registered trademark of Regeneron Pharmaceuticals, Inc.

***Every Second Counts!***<sup>®</sup>

### **Kiniksa Investor and Media Contact**

Rachel Frank  
(339) 970-9437  
[rfrank@kiniksa.com](mailto:rfrank@kiniksa.com)